Literature DB >> 21466489

Ulcerative colitis: pathogenesis.

Walter Fries1, Salvatore Comunale.   

Abstract

The pathogenesis of ulcerative is still poorly understood. With the introduction of new culture-independent techniques the research on the intestinal microbiota has revealed an important reduction of Bacteroidetes and Firmicutes leading to a reduced biodiversity and dysbiosis in these patients. Going in depth, the intestinal barrier is covered under physiologic conditions by a mostly sterile mucus layer. Besides a reduction of mucus thickness or an alteration in mucus composition hypothesized for human ulcerative colitis, new evidence coming from mouse models has introduced a novel concept based on cellular stress due to misfolded mucus-associated proteins opening a new research area for the epithelial cell lining. A dysregulated immune response involving the innate (e.g. toll-like receptors, dendritic cells, etc) and the adaptive immune system (e.g. effector T-cells, regulatory T-cells, eosinophils, neutrophils, etc) may follow or precede the macroscopic lesions. The immune response in ulcerative colitis is represented principally by secretion of interleukin-5 and -13 being the latter responsible for the direct cytotoxicity against the epithelial cells. In latter stages the role of interleukin-17 producing cells, apparently differently regulated compared with Crohn's disease, remains to be elucidated. Finally, human ulcerative colitis is characterized by the presence of various types of autoantibodies including pANCA, antibodies against goblet cells and the isoforms 1 and 5 of human tropomyosin. The pathogenic potential of these antibodies is still debated. The present review focus on new achievements in the various scenarios converging to the clinical and histopathological feature of ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466489     DOI: 10.2174/138945011796818261

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  11 in total

Review 1.  Mucosal immunology and probiotics.

Authors:  Maria Luisa Dongarrà; Valeria Rizzello; Letizia Muccio; Walter Fries; Antonio Cascio; Irene Bonaccorsi; Guido Ferlazzo
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

2.  Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients.

Authors:  Altug Cincin; Murat Sunbul; Tarık Kivrak; Halil Atas; Ibrahim Sari; Kursat Tigen; Tarik Kani; Hakan Akin; Nese Imeryuz; Yelda Basaran
Journal:  Dig Dis Sci       Date:  2014-07-15       Impact factor: 3.199

3.  Managing ulcerative colitis by increasing hydrogen production via oral administration of Acarbose.

Authors:  Jian-Hong Zhu; De-Qing Zhang; Wei-Chang Chen
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-08-12

4.  MiR-29a promotes intestinal epithelial apoptosis in ulcerative colitis by down-regulating Mcl-1.

Authors:  Bo Lv; Zhihui Liu; Shuping Wang; Fengbin Liu; Xiaojun Yang; Jiangtao Hou; Zhengkun Hou; Bin Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

5.  Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway.

Authors:  Jingjing Zhang; Wei Dou; Eryun Zhang; Aning Sun; Lili Ding; Xiaohui Wei; Guixin Chou; Sridhar Mani; Zhengtao Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-14       Impact factor: 4.052

6.  Acarbose: a new option in the treatment of ulcerative colitis by increasing hydrogen production.

Authors:  De-Qing Zhang; Jian-Hong Zhu; Wei-Chang Chen
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-10-01

7.  Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis.

Authors:  Yan Zhang; Zhongqiu Wang; Jun Liu; Shaoheng Zhang; Jiaxi Fei; Jing Li; Ting Zhang; Jide Wang; Pyong W Park; Ye Chen
Journal:  J Cell Mol Med       Date:  2016-08-25       Impact factor: 5.310

8.  Effects of Deoxyschisandrin on Visceral Sensitivity of Mice with Inflammatory Bowel Disease.

Authors:  Zhili Xu; Mingbo Zhang; Deqiang Dou; Tingguo Kang; Feng Li
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-04       Impact factor: 2.629

9.  Acetylcholinesterase Inhibitor Pyridostigmine Bromide Attenuates Gut Pathology and Bacterial Dysbiosis in a Murine Model of Ulcerative Colitis.

Authors:  Shashi P Singh; Hitendra S Chand; Santanu Banerjee; Hemant Agarwal; Veena Raizada; Sabita Roy; Mohan Sopori
Journal:  Dig Dis Sci       Date:  2019-10-23       Impact factor: 3.199

10.  Administration of neem (Azadirachta indica A. Juss) leaf extract decreases TNF-α and IL-6 expressions in dextran sodium sulfate-induced colitis in rats.

Authors:  Riska Habriel Ruslie; Darmadi Darmadi
Journal:  J Adv Vet Anim Res       Date:  2020-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.